Exposure to Neoadjuvant Oxaliplatin-Containing Chemotherapy, Does it Effect Intraperitoneal Hyperthermic Chemotherapy Perfusion?
Introduction Patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) are commonly exposed to oxaliplatin neoadjuvant chemotherapy (NAT) regimens. The impact of systemic exposure to oxaliplatin prior to HIPEC with oxaliplatin is unknown. Methods We conduct...
Gespeichert in:
| Veröffentlicht in: | Annals of surgical oncology 2023-04, Vol.30 (4), p.2486-2493 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2493 |
|---|---|
| container_issue | 4 |
| container_start_page | 2486 |
| container_title | Annals of surgical oncology |
| container_volume | 30 |
| creator | Mangieri, Christopher W. Valenzuela, Cristian D. Solsky, Ian B. Erali, Richard A. Votanopoulos, Konstantinos I. Shen, Perry Levine, Edward A. |
| description | Introduction
Patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) are commonly exposed to oxaliplatin neoadjuvant chemotherapy (NAT) regimens. The impact of systemic exposure to oxaliplatin prior to HIPEC with oxaliplatin is unknown.
Methods
We conducted a retrospective review of our institutional registry of CRS/HIPEC cases who received oxaliplatin-containing NAT, and compared patients who underwent HIPEC with oxaliplatin versus cases perfused with mitomycin C. The primary outcome was survival, defined by overall survival (OS) and disease-free survival (DFS). Subgroup analysis was performed based on primary tumor etiology and completeness of cytoreduction.
Results
A total of 333 cases satisfied the selection criteria—159 appendiceal primaries (all high-grade disease) and 174 colorectal cases. Thirty-one cases (9.3%) underwent HIPEC with oxaliplatin, with the remaining 302 cases (90.7%) receiving mitomycin C. Both cohorts were identical in regard to baseline characteristics, and both groups were alike in regard to NAT regimens and oxaliplatin exposure. There was no difference in survival outcomes. OS times were 2.9 (± 2.8) and 2.8 ( ± 3.6) years for oxaliplatin and mitomycin C perfusions, respectively (
p
= 0.94), and the 5-year OS rates were also similar at 9.7 and 18.5% (odds ratio [OR] 0.49, 95% confidence interval [CI] 0.14–1.67,
p
= 0.24) for oxaliplatin and mitomycin cases, respectively. Likewise, DFS findings were similar, with survival of 2.5 (± 4.5) and 1.8 (± 2.4) years for oxaliplatin and mitomycin perfusions, respectively (
p
= 0.21). There was no difference in 5-year DFS rates, at 10.5 and 7.8% (OR 1.39, 95% CI 0.30–6.56,
p
= 0.68) for oxaliplatin and mitomycin C, respectively. Subgroup analysis found minimal discordant findings from the main results.
Conclusion
This analysis found no discernable association with NAT oxaliplatin exposure in regard to survival outcomes following CRS/HIPEC stratified out by perfusion agent. |
| doi_str_mv | 10.1245/s10434-022-12933-y |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2753296405</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2788586332</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-cb3ef90045507fcb076ca80080342dec511be8a22f9cf356689dbd72a8f58f433</originalsourceid><addsrcrecordid>eNp9kT1v1TAUhiMEoh_wBxiQJRaGBvyZOBNClwutVLUMMFuOc9z6KrGD7aBm46fjcksrOjDZPn7e15aeqnpF8DtCuXifCOaM15jSmtCOsXp9Uh0SUUa8keRp2eNG1h1txEF1lNIOY9IyLJ5XB6zhkneYH1a_tjdzSEsElAO6gKCH3fJT-4wub_To5lFn5-tN8Fk77_wV2lzDFPI1RD2vJ-hTgIRcRltrwWR05nOZQ3Q5eNAjOl3L4RaenPknib5CtEtywX94UT2zekzw8m49rr5_3n7bnNbnl1_ONh_Pa8NakWvTM7AdxlwI3FrT47YxWmIsMeN0ACMI6UFqSm1nLBNNI7uhH1qqpRXScsaOq7f73jmGHwukrCaXDIyj9hCWpGgrGO0ajkVB3zxCd2GJvvyuUFIK2TBGC0X3lIkhpQhWzdFNOq6KYHXrR-39qOJH_fGj1hJ6fVe99BMM95G_QgrA9kAqV_4K4sPb_6n9DdvRneo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2788586332</pqid></control><display><type>article</type><title>Exposure to Neoadjuvant Oxaliplatin-Containing Chemotherapy, Does it Effect Intraperitoneal Hyperthermic Chemotherapy Perfusion?</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Mangieri, Christopher W. ; Valenzuela, Cristian D. ; Solsky, Ian B. ; Erali, Richard A. ; Votanopoulos, Konstantinos I. ; Shen, Perry ; Levine, Edward A.</creator><creatorcontrib>Mangieri, Christopher W. ; Valenzuela, Cristian D. ; Solsky, Ian B. ; Erali, Richard A. ; Votanopoulos, Konstantinos I. ; Shen, Perry ; Levine, Edward A.</creatorcontrib><description>Introduction
Patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) are commonly exposed to oxaliplatin neoadjuvant chemotherapy (NAT) regimens. The impact of systemic exposure to oxaliplatin prior to HIPEC with oxaliplatin is unknown.
Methods
We conducted a retrospective review of our institutional registry of CRS/HIPEC cases who received oxaliplatin-containing NAT, and compared patients who underwent HIPEC with oxaliplatin versus cases perfused with mitomycin C. The primary outcome was survival, defined by overall survival (OS) and disease-free survival (DFS). Subgroup analysis was performed based on primary tumor etiology and completeness of cytoreduction.
Results
A total of 333 cases satisfied the selection criteria—159 appendiceal primaries (all high-grade disease) and 174 colorectal cases. Thirty-one cases (9.3%) underwent HIPEC with oxaliplatin, with the remaining 302 cases (90.7%) receiving mitomycin C. Both cohorts were identical in regard to baseline characteristics, and both groups were alike in regard to NAT regimens and oxaliplatin exposure. There was no difference in survival outcomes. OS times were 2.9 (± 2.8) and 2.8 ( ± 3.6) years for oxaliplatin and mitomycin C perfusions, respectively (
p
= 0.94), and the 5-year OS rates were also similar at 9.7 and 18.5% (odds ratio [OR] 0.49, 95% confidence interval [CI] 0.14–1.67,
p
= 0.24) for oxaliplatin and mitomycin cases, respectively. Likewise, DFS findings were similar, with survival of 2.5 (± 4.5) and 1.8 (± 2.4) years for oxaliplatin and mitomycin perfusions, respectively (
p
= 0.21). There was no difference in 5-year DFS rates, at 10.5 and 7.8% (OR 1.39, 95% CI 0.30–6.56,
p
= 0.68) for oxaliplatin and mitomycin C, respectively. Subgroup analysis found minimal discordant findings from the main results.
Conclusion
This analysis found no discernable association with NAT oxaliplatin exposure in regard to survival outcomes following CRS/HIPEC stratified out by perfusion agent.</description><identifier>ISSN: 1068-9265</identifier><identifier>EISSN: 1534-4681</identifier><identifier>DOI: 10.1245/s10434-022-12933-y</identifier><identifier>PMID: 36484904</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Chemotherapy ; Colorectal Neoplasms - pathology ; Combined Modality Therapy ; Cytoreduction Surgical Procedures ; Etiology ; Humans ; Hyperthermia, Induced ; Hyperthermic Intraperitoneal Chemotherapy ; Medicine ; Medicine & Public Health ; Mitomycin - therapeutic use ; Mitomycin C ; Neoadjuvant Therapy ; Oncology ; Oxaliplatin ; Oxaliplatin - therapeutic use ; Perfusion ; Peritoneal Neoplasms - pathology ; Peritoneal Surface Malignancy ; Surgery ; Surgical Oncology ; Survival ; Survival Rate</subject><ispartof>Annals of surgical oncology, 2023-04, Vol.30 (4), p.2486-2493</ispartof><rights>Society of Surgical Oncology 2022. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2022. Society of Surgical Oncology.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-cb3ef90045507fcb076ca80080342dec511be8a22f9cf356689dbd72a8f58f433</citedby><cites>FETCH-LOGICAL-c375t-cb3ef90045507fcb076ca80080342dec511be8a22f9cf356689dbd72a8f58f433</cites><orcidid>0000-0003-0633-9454</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1245/s10434-022-12933-y$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1245/s10434-022-12933-y$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36484904$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mangieri, Christopher W.</creatorcontrib><creatorcontrib>Valenzuela, Cristian D.</creatorcontrib><creatorcontrib>Solsky, Ian B.</creatorcontrib><creatorcontrib>Erali, Richard A.</creatorcontrib><creatorcontrib>Votanopoulos, Konstantinos I.</creatorcontrib><creatorcontrib>Shen, Perry</creatorcontrib><creatorcontrib>Levine, Edward A.</creatorcontrib><title>Exposure to Neoadjuvant Oxaliplatin-Containing Chemotherapy, Does it Effect Intraperitoneal Hyperthermic Chemotherapy Perfusion?</title><title>Annals of surgical oncology</title><addtitle>Ann Surg Oncol</addtitle><addtitle>Ann Surg Oncol</addtitle><description>Introduction
Patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) are commonly exposed to oxaliplatin neoadjuvant chemotherapy (NAT) regimens. The impact of systemic exposure to oxaliplatin prior to HIPEC with oxaliplatin is unknown.
Methods
We conducted a retrospective review of our institutional registry of CRS/HIPEC cases who received oxaliplatin-containing NAT, and compared patients who underwent HIPEC with oxaliplatin versus cases perfused with mitomycin C. The primary outcome was survival, defined by overall survival (OS) and disease-free survival (DFS). Subgroup analysis was performed based on primary tumor etiology and completeness of cytoreduction.
Results
A total of 333 cases satisfied the selection criteria—159 appendiceal primaries (all high-grade disease) and 174 colorectal cases. Thirty-one cases (9.3%) underwent HIPEC with oxaliplatin, with the remaining 302 cases (90.7%) receiving mitomycin C. Both cohorts were identical in regard to baseline characteristics, and both groups were alike in regard to NAT regimens and oxaliplatin exposure. There was no difference in survival outcomes. OS times were 2.9 (± 2.8) and 2.8 ( ± 3.6) years for oxaliplatin and mitomycin C perfusions, respectively (
p
= 0.94), and the 5-year OS rates were also similar at 9.7 and 18.5% (odds ratio [OR] 0.49, 95% confidence interval [CI] 0.14–1.67,
p
= 0.24) for oxaliplatin and mitomycin cases, respectively. Likewise, DFS findings were similar, with survival of 2.5 (± 4.5) and 1.8 (± 2.4) years for oxaliplatin and mitomycin perfusions, respectively (
p
= 0.21). There was no difference in 5-year DFS rates, at 10.5 and 7.8% (OR 1.39, 95% CI 0.30–6.56,
p
= 0.68) for oxaliplatin and mitomycin C, respectively. Subgroup analysis found minimal discordant findings from the main results.
Conclusion
This analysis found no discernable association with NAT oxaliplatin exposure in regard to survival outcomes following CRS/HIPEC stratified out by perfusion agent.</description><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Chemotherapy</subject><subject>Colorectal Neoplasms - pathology</subject><subject>Combined Modality Therapy</subject><subject>Cytoreduction Surgical Procedures</subject><subject>Etiology</subject><subject>Humans</subject><subject>Hyperthermia, Induced</subject><subject>Hyperthermic Intraperitoneal Chemotherapy</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Mitomycin - therapeutic use</subject><subject>Mitomycin C</subject><subject>Neoadjuvant Therapy</subject><subject>Oncology</subject><subject>Oxaliplatin</subject><subject>Oxaliplatin - therapeutic use</subject><subject>Perfusion</subject><subject>Peritoneal Neoplasms - pathology</subject><subject>Peritoneal Surface Malignancy</subject><subject>Surgery</subject><subject>Surgical Oncology</subject><subject>Survival</subject><subject>Survival Rate</subject><issn>1068-9265</issn><issn>1534-4681</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kT1v1TAUhiMEoh_wBxiQJRaGBvyZOBNClwutVLUMMFuOc9z6KrGD7aBm46fjcksrOjDZPn7e15aeqnpF8DtCuXifCOaM15jSmtCOsXp9Uh0SUUa8keRp2eNG1h1txEF1lNIOY9IyLJ5XB6zhkneYH1a_tjdzSEsElAO6gKCH3fJT-4wub_To5lFn5-tN8Fk77_wV2lzDFPI1RD2vJ-hTgIRcRltrwWR05nOZQ3Q5eNAjOl3L4RaenPknib5CtEtywX94UT2zekzw8m49rr5_3n7bnNbnl1_ONh_Pa8NakWvTM7AdxlwI3FrT47YxWmIsMeN0ACMI6UFqSm1nLBNNI7uhH1qqpRXScsaOq7f73jmGHwukrCaXDIyj9hCWpGgrGO0ajkVB3zxCd2GJvvyuUFIK2TBGC0X3lIkhpQhWzdFNOq6KYHXrR-39qOJH_fGj1hJ6fVe99BMM95G_QgrA9kAqV_4K4sPb_6n9DdvRneo</recordid><startdate>20230401</startdate><enddate>20230401</enddate><creator>Mangieri, Christopher W.</creator><creator>Valenzuela, Cristian D.</creator><creator>Solsky, Ian B.</creator><creator>Erali, Richard A.</creator><creator>Votanopoulos, Konstantinos I.</creator><creator>Shen, Perry</creator><creator>Levine, Edward A.</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-0633-9454</orcidid></search><sort><creationdate>20230401</creationdate><title>Exposure to Neoadjuvant Oxaliplatin-Containing Chemotherapy, Does it Effect Intraperitoneal Hyperthermic Chemotherapy Perfusion?</title><author>Mangieri, Christopher W. ; Valenzuela, Cristian D. ; Solsky, Ian B. ; Erali, Richard A. ; Votanopoulos, Konstantinos I. ; Shen, Perry ; Levine, Edward A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-cb3ef90045507fcb076ca80080342dec511be8a22f9cf356689dbd72a8f58f433</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Chemotherapy</topic><topic>Colorectal Neoplasms - pathology</topic><topic>Combined Modality Therapy</topic><topic>Cytoreduction Surgical Procedures</topic><topic>Etiology</topic><topic>Humans</topic><topic>Hyperthermia, Induced</topic><topic>Hyperthermic Intraperitoneal Chemotherapy</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Mitomycin - therapeutic use</topic><topic>Mitomycin C</topic><topic>Neoadjuvant Therapy</topic><topic>Oncology</topic><topic>Oxaliplatin</topic><topic>Oxaliplatin - therapeutic use</topic><topic>Perfusion</topic><topic>Peritoneal Neoplasms - pathology</topic><topic>Peritoneal Surface Malignancy</topic><topic>Surgery</topic><topic>Surgical Oncology</topic><topic>Survival</topic><topic>Survival Rate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mangieri, Christopher W.</creatorcontrib><creatorcontrib>Valenzuela, Cristian D.</creatorcontrib><creatorcontrib>Solsky, Ian B.</creatorcontrib><creatorcontrib>Erali, Richard A.</creatorcontrib><creatorcontrib>Votanopoulos, Konstantinos I.</creatorcontrib><creatorcontrib>Shen, Perry</creatorcontrib><creatorcontrib>Levine, Edward A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of surgical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mangieri, Christopher W.</au><au>Valenzuela, Cristian D.</au><au>Solsky, Ian B.</au><au>Erali, Richard A.</au><au>Votanopoulos, Konstantinos I.</au><au>Shen, Perry</au><au>Levine, Edward A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Exposure to Neoadjuvant Oxaliplatin-Containing Chemotherapy, Does it Effect Intraperitoneal Hyperthermic Chemotherapy Perfusion?</atitle><jtitle>Annals of surgical oncology</jtitle><stitle>Ann Surg Oncol</stitle><addtitle>Ann Surg Oncol</addtitle><date>2023-04-01</date><risdate>2023</risdate><volume>30</volume><issue>4</issue><spage>2486</spage><epage>2493</epage><pages>2486-2493</pages><issn>1068-9265</issn><eissn>1534-4681</eissn><abstract>Introduction
Patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) are commonly exposed to oxaliplatin neoadjuvant chemotherapy (NAT) regimens. The impact of systemic exposure to oxaliplatin prior to HIPEC with oxaliplatin is unknown.
Methods
We conducted a retrospective review of our institutional registry of CRS/HIPEC cases who received oxaliplatin-containing NAT, and compared patients who underwent HIPEC with oxaliplatin versus cases perfused with mitomycin C. The primary outcome was survival, defined by overall survival (OS) and disease-free survival (DFS). Subgroup analysis was performed based on primary tumor etiology and completeness of cytoreduction.
Results
A total of 333 cases satisfied the selection criteria—159 appendiceal primaries (all high-grade disease) and 174 colorectal cases. Thirty-one cases (9.3%) underwent HIPEC with oxaliplatin, with the remaining 302 cases (90.7%) receiving mitomycin C. Both cohorts were identical in regard to baseline characteristics, and both groups were alike in regard to NAT regimens and oxaliplatin exposure. There was no difference in survival outcomes. OS times were 2.9 (± 2.8) and 2.8 ( ± 3.6) years for oxaliplatin and mitomycin C perfusions, respectively (
p
= 0.94), and the 5-year OS rates were also similar at 9.7 and 18.5% (odds ratio [OR] 0.49, 95% confidence interval [CI] 0.14–1.67,
p
= 0.24) for oxaliplatin and mitomycin cases, respectively. Likewise, DFS findings were similar, with survival of 2.5 (± 4.5) and 1.8 (± 2.4) years for oxaliplatin and mitomycin perfusions, respectively (
p
= 0.21). There was no difference in 5-year DFS rates, at 10.5 and 7.8% (OR 1.39, 95% CI 0.30–6.56,
p
= 0.68) for oxaliplatin and mitomycin C, respectively. Subgroup analysis found minimal discordant findings from the main results.
Conclusion
This analysis found no discernable association with NAT oxaliplatin exposure in regard to survival outcomes following CRS/HIPEC stratified out by perfusion agent.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>36484904</pmid><doi>10.1245/s10434-022-12933-y</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0003-0633-9454</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1068-9265 |
| ispartof | Annals of surgical oncology, 2023-04, Vol.30 (4), p.2486-2493 |
| issn | 1068-9265 1534-4681 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2753296405 |
| source | MEDLINE; SpringerLink Journals |
| subjects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use Chemotherapy Colorectal Neoplasms - pathology Combined Modality Therapy Cytoreduction Surgical Procedures Etiology Humans Hyperthermia, Induced Hyperthermic Intraperitoneal Chemotherapy Medicine Medicine & Public Health Mitomycin - therapeutic use Mitomycin C Neoadjuvant Therapy Oncology Oxaliplatin Oxaliplatin - therapeutic use Perfusion Peritoneal Neoplasms - pathology Peritoneal Surface Malignancy Surgery Surgical Oncology Survival Survival Rate |
| title | Exposure to Neoadjuvant Oxaliplatin-Containing Chemotherapy, Does it Effect Intraperitoneal Hyperthermic Chemotherapy Perfusion? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T18%3A26%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Exposure%20to%20Neoadjuvant%20Oxaliplatin-Containing%20Chemotherapy,%20Does%20it%20Effect%20Intraperitoneal%20Hyperthermic%20Chemotherapy%20Perfusion?&rft.jtitle=Annals%20of%20surgical%20oncology&rft.au=Mangieri,%20Christopher%20W.&rft.date=2023-04-01&rft.volume=30&rft.issue=4&rft.spage=2486&rft.epage=2493&rft.pages=2486-2493&rft.issn=1068-9265&rft.eissn=1534-4681&rft_id=info:doi/10.1245/s10434-022-12933-y&rft_dat=%3Cproquest_cross%3E2788586332%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2788586332&rft_id=info:pmid/36484904&rfr_iscdi=true |